News Releases

ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 8, 2016

LOS ANGELES, Feb. 1, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the 18th Annual BIO CEO & Investor Conference at 2:00 pm ET on Monday, February 8, 2016, at the Waldorf Astoria Hotel in New York City.

ImmunoCellular Therapeutics Logo

To access the live audio webcast of the BIO CEO presentation, please log on through a link located in the Investors section of ImmunoCellular's website at, under the Events & Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells, is open for patient screening. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. For more information please visit


ImmunoCellular Therapeutics, Ltd.
Jane Green.
Investor Relations

Logo -


SOURCE ImmunoCellular Therapeutics, Ltd.